{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:41:16Z","timestamp":1789908076475,"version":"4.0.1"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p>Lenalidomide (REVLIMID\u2122), an immunomodulatory compound targeting both cancer cells and their microenvironment, has substantial activity in several difficult\u2010to\u2010manage hematological malignancies. In previously treated multiple myeloma, lenalidomide produces high\u2010quality responses combined with sustained disease control. Recently, several randomized studies have demonstrated a clinical benefit of continuous lenalidomide treatment in newly diagnosed multiple myeloma. In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. It has a manageable safety profile, and its oral formulation reduces the burden on patients. Several phase III trials are ongoing in other indications currently underserved by conventional therapy, such as chronic lymphocytic leukemia, non\u2010Hodgkin's lymphoma, and prostate cancer. Several early\u2010stage studies are exploring lenalidomide alone and in combination across different hematological malignancies, solid tumors, and immune\u2010related disorders.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2011.05974.x","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T14:43:51Z","timestamp":1300805031000},"page":"76-82","source":"Crossref","is-referenced-by-count":72,"title":["A review of the history, properties, and use of the immunomodulatory compound lenalidomide"],"prefix":"10.1111","volume":"1222","author":[{"given":"Jerome B.","family":"Zeldis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.053"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.135"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/156800910791054239"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.1.380"},{"issue":"1","key":"e_1_2_8_9_2","first-page":"309","article-title":"Lenalidomide inhibits the multiple myeloma cell survival factor IRF4\/MUM1 [abstract]","volume":"9","author":"Lopez\u2010Girona A.","year":"2009","journal-title":"Clin. Lymph. Myeloma."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"e_1_2_8_11_2","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay A.G.","year":"2008","journal-title":"J. Clin. Invest."},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4184"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2005.01.002"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402295"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"issue":"2","key":"e_1_2_8_23_2","first-page":"566","article-title":"A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM) [abstract]","volume":"95","author":"Palumbo A.","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_8_24_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood.V116.21.37.37","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem hematopoietic cell transplant (AHSCT) for multiple myeloma (MM): CALGB 100104 [abstract]","volume":"116","author":"McCarthy P.L.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_25_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005\u201302 [abstract]","volume":"116","author":"Attal M.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041668"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-068833"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.6508"},{"issue":"3","key":"e_1_2_8_32_2","first-page":"10.29","article-title":"Safety and efficacy of slow dose\u2010escalation of lenalidomide for front\u2010line treatment in chronic lymphocytic leukemia (CLL): results of a phase II study [abstract]","volume":"94","author":"Chen C.I.","year":"2009","journal-title":"Haematologica."},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903406806"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8036"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25377"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9200-x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009335001"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e13155"},{"issue":"10","key":"e_1_2_8_42_2","first-page":"7","article-title":"A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings","volume":"5","author":"Stadtmauer E.A.","year":"2007","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_8_44_2","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.V112.11.3708.3708","article-title":"Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone [abstract]","volume":"112","author":"Ishak J.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.491-499"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7561"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V114.22.614.614","article-title":"Multicenter, randomized, open\u2010label, phase III trial of lenalidomide\u2010dexamethasone (len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract]","volume":"114","author":"Mateos M.V.","year":"2009","journal-title":"Blood"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2011.05974.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2011.05974.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T20:12:16Z","timestamp":1694981536000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2011.05974.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1749-6632.2011.05974.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2011.05974.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}